Abstract:OBJECTIVES: Cell-free DNA based non-invasive prenatal testing (NIPT) has been shown with closeto-diagnosis sensitivity and specificity in detecting fetal T21, T18, and T13. Future development of this technology focuses on detection of other chromosomal aneuploidies, and more importantly chromosome copy number variants (CNVs) and single-gene mutations. Validation studies were carried out to demonstrate the feasibility of detecting CNVs and single-gene disease by exploiting the cell-free DNA testing strategy and existing NIPT platforms. METHOD: For testing CNVs, 35 plasma samples with known fetal CNVs (>10 Mb in size) were recruited, together with 1077 plasma samples with normal fetal karyotypes as the control. The samples were blindly tested using the routine NIPT testing pipelines adopted at the clinical laboratories of BGI, and analyzed with the proprietary FCAPS protocol. Results were compared to the karyotyping results to calculate the sensitivity and specificity of the NIPT test. For testing single-gene disease, we developed a unique haplotype-assisted approach which was validated in a Maple Syrup Urine Disease (MSUD) case. In a trio family (father, mother in early pregnancy, and proband), targeted sequencing (180X) of the known genes causing MSUD was used to identify the disease causative mutations in the proband child and parents. At 13 gestational weeks, maternal plasma DNA and genomic DNA of the trio family were tested with a customized array at the sequencing depth of 40X and 20X respectively to retrieve the SNPs information for the purpose of parental haplotypes deduction. Linkage analysis and Hidden Markov Model were then used to construct the fetal genotype and haplotype flanking the MSUD mutation region. RESULTS: For CNV detection, with on average 4–5 M reads per sample and the existing NIPT platforms, we were able to use the FCAPS analytic protocol to identify 32 positive samples in total of 35, and generated 6 false positive cases, leading to overall sensitivity and specificity of 91.4% and 99.4% respectively. False positive rate and false negative rate of the test were 0.56% and 0.28% respectively. We also showed that with an increased sequencing depth, the detection power of the test can be further improved. In the MUSD case, deep targeted sequencing in the trio family identified that the proband child carries a missense mutation and a large deletion on BCKDHA gene, which were inherited from the mother and father respectively. With the SNP markers of the proband and parents, parental haplotype of chromosome 19 in 6148 loci were recovered. After fetal haplotype construction, the same alleles as that of the proband in the causative gene BCKDHA were inherited to the fetus, indicating that the fetus is a MSUD patient. This result was later confirmed by invasive diagnosis, and led to a well-informed decision after post-test counselling. CONCLUSIONS: We demonstrate the successful application of NIPT in detection of CNVs larger than 10 Mb without changing much to the current pipelines of aneuploidy detection. It has the potential to be integrated into the current NIPT test and offer extra benefits to the clinical service. The haplotype-assisted approach we developed requires minimum genetic information to accurately predict fetal condition. It has the clinical potential for noninvasive prenatal diagnosis of single gene disease for family with a proband child and seeks a second healthy child.

Comparison of exon-level copy number variants in CytoScan XON assay and next-generation sequencing in clinical samples

Accuracy Of Cnv Detection From Gwas Data

Evaluation of Copy Number Variant Detection from Panel‐based Next‐generation Sequencing Data

Noninvasive detection of chromosomal CNV and single gene disease by massively parallel sequencing of cfDNA

Copy Number Aberrations from Affymetrix SNP 6.0 Genotyping Data-How Accurate Are Commonly Used Prediction Approaches?

Evaluation of Somatic Copy Number Estimation Tools for Whole-Exome Sequencing Data

An evaluation of copy number variation detection tools from whole-exome sequencing data.

High Detection Rate of Copy Number Variations Using Capture Sequencing Data: A Retrospective Study

SeqCNV: a Novel Method for Identification of Copy Number Variations in Targeted Next-Generation Sequencing Data

Low-Pass Genome Sequencing: Validation and Diagnostic Utility from 409 Clinical Cases of Low-Pass Genome Sequencing for the Detection of Copy Number Variants to Replace Constitutional Microarray

High positive predictive value of CNVs detected by clinical exome sequencing in suspected genetic diseases

Detection of Genome-Wide Copy Number Variants in Myeloid Malignancies Using Next-Generation Sequencing

Genome-Wide Copy Number Variation Detection Using NGS: Data Analysis and Interpretation.

Comparative Studies of Copy Number Variation Detection Methods for Next-Generation Sequencing Technologies

Evaluation of tools for identifying large copy number variations from ultra-low-coverage whole-genome sequencing data

Copy number variation sequencing for comprehensive diagnosis of chromosome disease syndromes.

A Remark on Copy Number Variation Detection Methods

Comprehensive Assessment of Somatic Copy Number Variation Calling Using Next-Generation Sequencing Data

Evaluation of three read-depth based CNV detection tools using whole-exome sequencing data

A Sparse Model Based Detection of Copy Number Variations from Exome Sequencing Data

Copy Number Variant and Runs of Homozygosity Detection by Microarrays Enabled More Precise Molecular Diagnoses in 11,020 Clinical Exome Cases